Cancer – H-42691: A Trial of Atovaquone (MEPRON) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents and Young Adults

What is the goal of this study?

The goals of this study are:

• To collect data on the patient and family experience of giving daily atovaquone to patients during their first month of AML treatment.
• To collect information about whether atovaquone kills cancer cells from children with AML, using research laboratory studies.
• To learn more about how atovaquone kills cancer cells from children with AML.
• To help determine the best way to include atovaquone in pediatric AML treatments in the future.

Who can join the study?

This study may be a good fit for children and young adults who:

• Are between 1 month and 21 years old
• Are newly diagnosed with acute myelogenous leukemia

What will happen if my child takes part in this study?

You can read more about this study on clinicaltrials.gov.

Who can I contact for more information?

To learn more, call 206-987-2106 or email the study coordinator.